Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 261

1.

Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer's Disease in EXPEDITION 3.

Liu-Seifert H, Siemers E, Sundell K, Mynderse M, Cummings J, Mohs R, Aisen P.

J Prev Alzheimers Dis. 2018;5(3):184-187. doi: 10.14283/jpad.2018.22.

PMID:
29972211
2.

A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease.

Chen YF, Ni X, Fleisher AS, Zhou W, Aisen P, Mohs R.

Alzheimers Dement (N Y). 2018 Jan 18;4:46-53. doi: 10.1016/j.trci.2017.12.002. eCollection 2018.

3.

New thinking about thinking, part two. Theoretical articles for Alzheimer's & Dementia.

Khachaturian AS, Hayden KM, Mielke MM, Tang Y, Lutz MW, Gold M, Kukull WA, Mohs R, Gauthier S, Molinuevo JL, Zetterberg H, Khachaturian ZS.

Alzheimers Dement. 2018 Jun;14(6):703-706. doi: 10.1016/j.jalz.2018.05.002. Epub 2018 May 26. No abstract available.

PMID:
29842864
4.

Future prospects and challenges for Alzheimer's disease drug development in the era of the NIA-AA Research Framework.

Khachaturian AS, Hayden KM, Mielke MM, Tang Y, Lutz MW, Gustafson DR, Kukull WA, Mohs R, Khachaturian ZS.

Alzheimers Dement. 2018 Apr;14(4):532-534. doi: 10.1016/j.jalz.2018.03.003. No abstract available.

PMID:
29653605
5.

Drug discovery and development: Role of basic biological research.

Mohs RC, Greig NH.

Alzheimers Dement (N Y). 2017 Nov 11;3(4):651-657. doi: 10.1016/j.trci.2017.10.005. eCollection 2017 Nov. Review.

6.

Randomized controlled trials in mild cognitive impairment: Sources of variability.

Petersen RC, Thomas RG, Aisen PS, Mohs RC, Carrillo MC, Albert MS; Alzheimer's Disease Neuroimaging Initiative (ADNI) and Foundation for NIH (FNIH) Biomarkers Consortium AD MCI Placebo Data Analysis Project Team.

Neurology. 2017 May 2;88(18):1751-1758. doi: 10.1212/WNL.0000000000003907. Epub 2017 Apr 5.

7.

Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence.

Post A, Smart TS, Jackson K, Mann J, Mohs R, Rorick-Kehn L, Statnick M, Anton R, O'Malley SS, Wong CJ.

Alcohol Clin Exp Res. 2016 Sep;40(9):1935-44. doi: 10.1111/acer.13147. Epub 2016 Jul 20.

PMID:
27435979
8.

Toward a consensus recommendation for defining the asymptomatic-preclinical phases of putative Alzheimer's disease?

Khachaturian ZS, Mesulam MM, Mohs RC, Khachaturian AS.

Alzheimers Dement. 2016 Mar;12(3):213-5. doi: 10.1016/j.jalz.2016.02.003. No abstract available.

PMID:
27012483
9.

Correlation between Cognition and Function across the Spectrum of Alzheimer's Disease.

Liu-Seifert H, Siemers E, Selzler K, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R.

J Prev Alzheimers Dis. 2016;3(3):138-144. doi: 10.14283/jpad.2016.99.

PMID:
29205252
10.

The Special Topics Section of Alzheimer's & Dementia.

Khachaturian ZS, Mesulam MM, Khachaturian AS, Mohs RC.

Alzheimers Dement. 2015 Nov;11(11):1261-4. doi: 10.1016/j.jalz.2015.10.002. No abstract available.

PMID:
26589667
11.

A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies.

Post A, Smart TS, Krikke-Workel J, Dawson GR, Harmer CJ, Browning M, Jackson K, Kakar R, Mohs R, Statnick M, Wafford K, McCarthy A, Barth V, Witkin JM.

Neuropsychopharmacology. 2016 Jun;41(7):1803-12. doi: 10.1038/npp.2015.348. Epub 2015 Nov 20.

12.

Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.

Liu-Seifert H, Siemers E, Price K, Han B, Selzler KJ, Henley D, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;47(1):205-14. doi: 10.3233/JAD-142508.

13.

Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's disease.

Doody RS, Raman R, Sperling RA, Seimers E, Sethuraman G, Mohs R, Farlow M, Iwatsubo T, Vellas B, Sun X, Ernstrom K, Thomas RG, Aisen PS; Alzheimer’s Disease Cooperative Study.

Alzheimers Res Ther. 2015 Jun 10;7(1):36. doi: 10.1186/s13195-015-0121-6. eCollection 2015.

14.

The future is now: model-based clinical trial design for Alzheimer's disease.

Romero K, Ito K, Rogers JA, Polhamus D, Qiu R, Stephenson D, Mohs R, Lalonde R, Sinha V, Wang Y, Brown D, Isaac M, Vamvakas S, Hemmings R, Pani L, Bain LJ, Corrigan B; Alzheimer's Disease Neuroimaging Initiative; Coalition Against Major Diseases.

Clin Pharmacol Ther. 2015 Mar;97(3):210-4. doi: 10.1002/cpt.16. Epub 2014 Dec 27.

PMID:
25669145
15.

2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease.

Alzheimer's Association National Plan Milestone Workgroup, Fargo KN, Aisen P, Albert M, Au R, Corrada MM, DeKosky S, Drachman D, Fillit H, Gitlin L, Haas M, Herrup K, Kawas C, Khachaturian AS, Khachaturian ZS, Klunk W, Knopman D, Kukull WA, Lamb B, Logsdon RG, Maruff P, Mesulam M, Mobley W, Mohs R, Morgan D, Nixon RA, Paul S, Petersen R, Plassman B, Potter W, Reiman E, Reisberg B, Sano M, Schindler R, Schneider LS, Snyder PJ, Sperling RA, Yaffe K, Bain LJ, Thies WH, Carrillo MC.

Alzheimers Dement. 2014 Oct;10(5 Suppl):S430-52. doi: 10.1016/j.jalz.2014.08.103.

16.

Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia.

Liu-Seifert H, Siemers E, Sundell K, Price K, Han B, Selzler K, Aisen P, Cummings J, Raskin J, Mohs R.

J Alzheimers Dis. 2015;43(3):949-55. doi: 10.3233/JAD-140792.

PMID:
25125457
17.

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R; Alzheimer's Disease Cooperative Study Steering Committee; Solanezumab Study Group.

N Engl J Med. 2014 Jan 23;370(4):311-21. doi: 10.1056/NEJMoa1312889.

18.

A phase 3 trial of semagacestat for treatment of Alzheimer's disease.

Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS; Alzheimer's Disease Cooperative Study Steering Committee, Siemers E, Sethuraman G, Mohs R; Semagacestat Study Group.

N Engl J Med. 2013 Jul 25;369(4):341-50. doi: 10.1056/NEJMoa1210951.

19.

Standardizing the use of the Continuous Performance Test in schizophrenia research: a validation study.

Kahn PV, Walker TM, Williams TS, Cornblatt BA, Mohs RC, Keefe RS.

Schizophr Res. 2012 Dec;142(1-3):153-8. doi: 10.1016/j.schres.2012.09.009. Epub 2012 Oct 3.

PMID:
23040735
20.

The effect of duloxetine treatment on cognition in patients with fibromyalgia.

Mohs R, Mease P, Arnold LM, Wang F, Ahl J, Gaynor PJ, Wohlreich MM.

Psychosom Med. 2012 Jul-Aug;74(6):628-34. doi: 10.1097/PSY.0b013e31825b9855. Epub 2012 Jun 28.

PMID:
22753629
21.

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER.

Alzheimers Dement. 2012 Jul;8(4):261-71. doi: 10.1016/j.jalz.2011.09.224. Epub 2012 Jun 5.

PMID:
22672770
22.

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH.

Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21.

23.

Revision of the criteria for Alzheimer’s disease: A symposium.

DeKosky ST, Carrillo MC, Phelps C, Knopman D, Petersen RC, Frank R, Schenk D, Masterman D, Siemers ER, Cedarbaum JM, Gold M, Miller DS, Morimoto BH, Khachaturian AS, Mohs RC.

Alzheimers Dement. 2011 Jan;7(1):e1-12.

PMID:
21322828
24.

Developing a national strategy to prevent dementia: Leon Thal Symposium 2009.

Khachaturian ZS, Barnes D, Einstein R, Johnson S, Lee V, Roses A, Sager MA, Shankle WR, Snyder PJ, Petersen RC, Schellenberg G, Trojanowski J, Aisen P, Albert MS, Breitner JC, Buckholtz N, Carrillo M, Ferris S, Greenberg BD, Grundman M, Khachaturian AS, Kuller LH, Lopez OL, Maruff P, Mohs RC, Morrison-Bogorad M, Phelps C, Reiman E, Sabbagh M, Sano M, Schneider LS, Siemers E, Tariot P, Touchon J, Vellas B, Bain LJ.

Alzheimers Dement. 2010 Mar;6(2):89-97. doi: 10.1016/j.jalz.2010.01.008.

25.

Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.

Mohs RC, Shiovitz TM, Tariot PN, Porsteinsson AP, Baker KD, Feldman PD.

Am J Geriatr Psychiatry. 2009 Sep;17(9):752-9. doi: 10.1097/JGP.0b013e3181aad585.

PMID:
19700948
26.

Scales as outcome measures for Alzheimer's disease.

Black R, Greenberg B, Ryan JM, Posner H, Seeburger J, Amatniek J, Resnick M, Mohs R, Miller DS, Saumier D, Carrillo MC, Stern Y.

Alzheimers Dement. 2009 Jul;5(4):324-39. doi: 10.1016/j.jalz.2009.05.667.

PMID:
19560103
27.

A roadmap for the prevention of dementia II: Leon Thal Symposium 2008.

Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Roses A, Simpkins JW, Schneider LS, Albert MS, Egge R, Deves A, Ferris S, Greenberg BD, Johnson C, Kukull WA, Poirier J, Schenk D, Thies W, Gauthier S, Gilman S, Bernick C, Cummings JL, Fillit H, Grundman M, Kaye J, Mucke L, Reisberg B, Sano M, Pickeral O, Petersen RC, Mohs RC, Carrillo M, Corey-Bloom JP, Foster NL, Jacobsen S, Lee V, Potter WZ, Sabbagh MN, Salmon D, Trojanowski JQ, Wexler N, Bain LJ.

Alzheimers Dement. 2009 Mar;5(2):85-92. doi: 10.1016/j.jalz.2009.01.021.

28.

Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function.

Kleinman L, Lieberman J, Dube S, Mohs R, Zhao Y, Kinon B, Carpenter W, Harvey PD, Green MF, Keefe RS, Frank L, Bowman L, Revicki DA.

Schizophr Res. 2009 Feb;107(2-3):275-85. doi: 10.1016/j.schres.2008.10.002. Epub 2008 Nov 14.

PMID:
19013769
29.

A perspective on risks that impede development of drugs to modify the course of Alzheimer's disease: can they be reduced?

Mohs RC.

Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S85-7. doi: 10.1016/j.jalz.2007.11.011. Epub 2007 Dec 21. Review.

PMID:
18632007
30.

A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium.

Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Fillit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, Hyman B, Kuller L, Schenk D, Snyder S, Thomas RG, Tuszynski MH, Vellas B, Wurtman RJ, Snyder PJ, Frank RA, Albert M, Doody R, Ferris S, Kaye J, Koo E, Morrison-Bogorad M, Reisberg B, Salmon DP, Gilman S, Mohs R, Aisen PS, Breitner JC, Cummings JL, Kawas C, Phelps C, Poirier J, Sabbagh M, Touchon J, Khachaturian AS, Bain LJ.

Alzheimers Dement. 2008 May;4(3):156-63. doi: 10.1016/j.jalz.2008.03.005. No abstract available.

31.

Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years.

Fillenbaum GG, van Belle G, Morris JC, Mohs RC, Mirra SS, Davis PC, Tariot PN, Silverman JM, Clark CM, Welsh-Bohmer KA, Heyman A.

Alzheimers Dement. 2008 Mar;4(2):96-109. doi: 10.1016/j.jalz.2007.08.005.

32.

Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.

Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, Rotz BT, Mohs RC.

Am J Psychiatry. 2007 Jun;164(6):900-9.

PMID:
17541049
33.

AMPA potentiator treatment of cognitive deficits in Alzheimer disease.

Chappell AS, Gonzales C, Williams J, Witte MM, Mohs RC, Sperling R.

Neurology. 2007 Mar 27;68(13):1008-12.

PMID:
17389305
34.

Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease.

Mohs RC, Kawas C, Carrillo MC.

Alzheimers Dement. 2006 Jul;2(3):131-9. doi: 10.1016/j.jalz.2006.04.003.

PMID:
19595870
35.

Commentary on "Diagnosis of Alzheimer's disease: two decades of progress".

Mohs RC.

Alzheimers Dement. 2005 Oct;1(2):116-7. doi: 10.1016/j.jalz.2005.09.003. No abstract available.

PMID:
19595839
36.

Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology.

Beeri MS, Silverman JM, Davis KL, Marin D, Grossman HZ, Schmeidler J, Purohit DP, Perl DP, Davidson M, Mohs RC, Haroutunian V.

J Gerontol A Biol Sci Med Sci. 2005 Apr;60(4):471-5.

37.
38.

Neuropsychological test performance in healthy elderly volunteers before and after donepezil administration: a randomized, controlled study.

Beglinger LJ, Tangphao-Daniels O, Kareken DA, Zhang L, Mohs R, Siemers ER.

J Clin Psychopharmacol. 2005 Apr;25(2):159-65.

PMID:
15738747
39.

Neuropsychological test performance in healthy volunteers before and after donepezil administration.

Beglinger LJ, Gaydos BL, Kareken DA, Tangphao-Daniels O, Siemers ER, Mohs RC.

J Psychopharmacol. 2004 Mar;18(1):102-8.

PMID:
15107192
40.

Executive dysfunction in Alzheimer disease.

Swanberg MM, Tractenberg RE, Mohs R, Thal LJ, Cummings JL.

Arch Neurol. 2004 Apr;61(4):556-60.

41.

Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials.

Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR Jr, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ; Alzheimer's Disease Cooperative Study.

Arch Neurol. 2004 Jan;61(1):59-66.

PMID:
14732621
42.

Cognitive assessment of geriatric schizophrenic patients with severe impairment.

Bowie CR, Harvey PD, Moriarty PJ, Parrella M, White L, Mohs RC, Davis KL.

Arch Clin Neuropsychol. 2002 Oct;17(7):611-23.

PMID:
14591846
43.

Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale.

Keefe RS, Mohs RC, Bilder RM, Harvey PD, Green MF, Meltzer HY, Gold JM, Sano M.

Schizophr Bull. 2003;29(1):45-55.

PMID:
12908660
44.

Striatal size, glucose metabolic rate, and verbal learning in normal aging.

Brickman AM, Buchsbaum MS, Shihabuddin L, Hazlett EA, Borod JC, Mohs RC.

Brain Res Cogn Brain Res. 2003 Jun;17(1):106-16.

PMID:
12763197
45.

Cognitive burden and excess Lewy-body pathology in the Lewy-body variant of Alzheimer disease.

Serby M, Brickman AM, Haroutunian V, Purohit DP, Marin D, Lantz M, Mohs RC, Davis KL.

Am J Geriatr Psychiatry. 2003 May-Jun;11(3):371-4.

PMID:
12724118
46.

Caspase gene expression in the brain as a function of the clinical progression of Alzheimer disease.

Pompl PN, Yemul S, Xiang Z, Ho L, Haroutunian V, Purohit D, Mohs R, Pasinetti GM.

Arch Neurol. 2003 Mar;60(3):369-76.

PMID:
12633148
47.

Familial patterns of risk in very late-onset Alzheimer disease.

Silverman JM, Smith CJ, Marin DB, Mohs RC, Propper CB.

Arch Gen Psychiatry. 2003 Feb;60(2):190-7.

PMID:
12578437
48.

Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline.

Parvathy S, Davies P, Haroutunian V, Purohit DP, Davis KL, Mohs RC, Park H, Moran TM, Chan JY, Buxbaum JD.

Arch Neurol. 2001 Dec;58(12):2025-32. Erratum in: Arch Neurol 2002 Feb;59(2):202.

PMID:
11735776
49.

Current concepts in mild cognitive impairment.

Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B.

Arch Neurol. 2001 Dec;58(12):1985-92. Review.

PMID:
11735772
50.

Reliability and validity of a chronic care facility adaptation of the Clinical Dementia Rating scale.

Marin DB, Flynn S, Mare M, Lantz M, Hsu MA, Laurans M, Paredes M, Shreve T, Zaklad GR, Mohs RC.

Int J Geriatr Psychiatry. 2001 Aug;16(8):745-50.

PMID:
11536340

Supplemental Content

Support Center